BACE1 and Alzheimer disease: Β-secretase cleavage, a fundamental step in Aβ production, was already the subject of research when referring to BACE inhibitors (see below), and although clinical trials conducted so far were discontinued for safety reasons, BACE1 remains a well-validated therapeutic target for AD [51].